Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

619 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.
Cesini L, Carmosino I, Breccia M, De Benedittis D, Mohamed S, De Luca ML, Colafigli G, Molica M, Scalzulli E, Massaro F, Mariggiò E, Rizzo L, Loglisci MG, Scamuffa MC, Vozella F, Diverio D, Mancini M, Alimena G, Foà R, Latagliata R. Cesini L, et al. Among authors: rizzo l. Oncol Res Treat. 2019;42(12):660-664. doi: 10.1159/000502801. Epub 2019 Oct 8. Oncol Res Treat. 2019. PMID: 31593970
Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia.
Giona F, Malaspina F, Putti MC, Ladogana S, Mura R, Burnelli R, Vacca N, Rizzo L, Bianchi S, Moleti ML, Testi AM, Biondi A, Locatelli F, Saglio G, Foà R. Giona F, et al. Among authors: rizzo l. Br J Haematol. 2020 Mar;188(6):e101-e105. doi: 10.1111/bjh.16388. Epub 2020 Feb 22. Br J Haematol. 2020. PMID: 32087030 Free article. No abstract available.
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?
Campagna A, De Benedittis D, Fianchi L, Scalzulli E, Rizzo L, Niscola P, Piccioni AL, Di Veroli A, Mancini S, Villivà N, Martini T, Mohamed S, Carmosino I, Criscuolo M, Fenu S, Aloe Spiriti MA, Buccisano F, Mancini M, Tafuri A, Breccia M, Poloni A, Latagliata R. Campagna A, et al. Among authors: rizzo l. J Clin Med. 2022 May 5;11(9):2596. doi: 10.3390/jcm11092596. J Clin Med. 2022. PMID: 35566719 Free PMC article.
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.
Scalzulli E, Molica M, Alunni Fegatelli D, Colafigli G, Rizzo L, Mancini M, Efficace F, Latagliata R, Foà R, Breccia M. Scalzulli E, et al. Among authors: rizzo l. Ann Hematol. 2019 Aug;98(8):1919-1925. doi: 10.1007/s00277-019-03724-9. Epub 2019 Jun 5. Ann Hematol. 2019. PMID: 31168652
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
Scalzulli E, Caocci G, Efficace F, Rizzo L, Colafigli G, Di Prima A, Pepe S, Fegatelli DA, Carmosino I, Diverio D, Latagliata R, La Nasa G, Martelli M, Foà R, Breccia M. Scalzulli E, et al. Among authors: rizzo l. Ann Hematol. 2021 May;100(5):1213-1219. doi: 10.1007/s00277-021-04477-0. Epub 2021 Mar 7. Ann Hematol. 2021. PMID: 33677654
619 results